Search

SABCS 2024 Highlights - DESTINY-Breast06, DESTINY-Breast12, PATINA with Dr. Sara Tolaney


Keypoints: 

29737

1.⁠ ⁠DESTINY-Breast06 - An update on the efficacy of T-DXd in HER2 low and ultra-low breast cancer patients, highlighting its potential to change treatment paradigms for endocrine refractory disease.
2.⁠ ⁠DESTINY-Breast12 - Exploring the robust intracranial activity of T-DXd in patients with brain metastases and its impact on quality of life.
3.⁠ ⁠PATINA Trial - A groundbreaking study on the use of CDK4-6 inhibitors in combination with trastuzumab and pertuzumab for ER-positive, HER2-positive breast cancer, showcasing impressive progression-free survival rates.

In this episode of the Oncology Brothers podcast, we had the pleasure of welcoming Dr. Sara Tolaney from Dana-Farber Cancer Institute to discuss key breast cancer studies presented at the San Antonio Breast Cancer Symposium 2024.

We kicked off the conversation with an in-depth look at the DESTINY-Breast06 study, which focused on T-DXd (trastuzumab deruxtecan) in patients with HER2 low and ultra-low breast cancer. Dr. Tolaney highlighted the study's unique design, which included patients who had progressed through endocrine therapy and were randomized to receive either T-DXd or standard chemotherapy. The results showed that T-DXd significantly outperformed standard chemotherapy, particularly in patients who were endocrine refractory, suggesting a shift in treatment strategies for these patients.

Next, we explored the DESTINY-Breast12 study, which examined the efficacy of T-DXd in patients with brain metastases. Dr. Tolaney shared that this study provided robust data, showing a 70% intracranial objective response rate and a 17-month progression-free survival. Importantly, the quality of life for patients receiving T-DXd remained stable, indicating that the treatment not only extends survival but also maintains patients' well-being.

Finally, we discussed the practice-changing PATINA trial, which investigated the use of CDK4-6 inhibitors in combination with trastuzumab and endocrine therapy for ER-positive, HER2-positive breast cancer. The trial revealed an impressive progression-free survival of 44 months, suggesting a new standard of care for this patient population.

Throughout the episode, we emphasized the importance of understanding HER2 expression levels and the need for pathologists to adapt their reporting to include ultra-low classifications. We also touched on the safety profiles of various CDK4-6 inhibitors and the potential for future studies to further refine treatment algorithms.

Overall, this episode provided valuable insights into the evolving landscape of breast cancer treatment, highlighting the significance of recent studies and their implications for clinical practice. Thank you for joining us, and we look forward to sharing more updates in future episodes!